Every year almost 500,000 new patients are diagnosed with hepatocellular carcinoma (HCC),
a primary malignancy of the liver that is associated with a poor prognosis. Numerous …

Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New
treatment options are becoming available, and there is a need to characterize the …

Nowadays, liver cancer, cirrhosis and other liver‐related diseases are the fifth most common
cause of mortality in the UK. Furthermore, chronic liver diseases (CLDs) are one of the …

Background Immune checkpoint blockade therapy has shown promising results in patients
with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of …

The liver is the largest solid organ in the body, yet it remains incompletely characterized.
Here we present a spatial proteogenomic atlas of the healthy and obese human and murine …

Acute‐on‐chronic liver failure (ACLF) in cirrhosis is characterized by acute decompensation
(AD), organ failure(s), and high short‐term mortality. Recently, we have proposed (systemic …

Background Tivantinib (ARQ 197), a selective oral inhibitor of MET, has shown promising
antitumour activity in hepatocellular carcinoma as monotherapy and in combination with …

The disease burden of hepatitis C virus ( HCV ) is expected to increase as the infected population
ages. A modelling approach was used to estimate the total number of viremic infections…

Metabolic-associated fatty liver disease (MAFLD) represents a spectrum of disease states
ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). Hepatic macrophages, …

Background & Aims Acute decompensation (AD) of cirrhosis is defined as the acute
development of ascites, gastrointestinal hemorrhage, hepatic encephalopathy, infection or any …